Results of 2025. Development of Medical Data Exchange Services

Oleg Kuznetsov, Head of Medical Data Exchange Services at Netrika Medicine, talks about the development in 2025 of the services “N3.Exchange with the High-Cost Nosologies Registry” and “N3.Prescription Data Exchange. Stock Balances”, as well as the development of data exchange transcoder modules and the team’s plans for the coming year.

Strategic Growth and Partnership

For Netrika Medicine, 2025 became a stage of strategic growth in the commercial market. Our expertise has been strengthened through a partnership with N3.Health, a technology partner that uses the N3.Healthcare integration platform as the foundation for digitalizing more than 9,500 private clinics.

This partnership allows us not only to develop services but also to create solutions of a new level. Our focus is on building a seamless information environment, where data from corporate healthcare (private clinics) and government systems operate together in real time for the benefit of patients.

High-Cost Nosologies Registry: Federal-Level Monitoring in Real Time

One of the key achievements of the year was participation in large-scale contracts for the development of regional healthcare subsystems.

In particular, as part of a project in the Leningrad Region, a fundamentally new product was created — a service for data exchange with the High-Cost Nosologies Registry.

These are rare and severe diseases whose treatment is financed from the federal budget. The service ensures the transfer of data on 14 such diseases from regional systems to the federal registry.

During the year, we completed the full cycle — from concept to industrial operation. Our new product now enables medical organizations to directly generate and transmit data on pharmaceutical demand.

The solution is already ready for scaling and implementation in other regions.

Transcoders: “Translators” of Data Between Public and Commercial Healthcare

Another development direction is the creation of transcoders.

These are specialized modules that ensure secure and convenient data exchange between different medical systems. They connect laboratory and diagnostic systems of the private sector (operating on the N3.Health platform) with government healthcare subsystems.

As a result, a referral from a public clinic to a commercial laboratory center, the completion of diagnostic testing, and the return of results to the physician become a fully automated end-to-end process.

For patients: waiting time for test results is reduced. There is no longer a need to collect paper forms and bring them to the doctor.

For public clinics: the load on their own laboratories decreases, and they gain the ability to use the capacity of private partner networks, especially during peak periods or for complex tests.

For commercial centers: there is an automatic flow of requests from the government healthcare system and a legitimate channel for data exchange.

Our expertise enables fast implementation without complexity for customers. In 2025, we not only developed this technology but also scaled it to four regions: Chelyabinsk Region, Saint Petersburg, Khabarovsk Territory, and Zabaykalsky Territory.

The key principle is that we take on the entire technical complexity of integration. Implementation takes place without the need to modify internal systems of clinics and laboratories, saving time and budget.

Prescription Data Exchange: A Closed Digital Cycle and Control of Drug Stock

In 2025, we introduced a prescription data exchange transcoder, which for the first time in Russia created a complete digital cycle for commercial prescriptions.

A pilot project in the Zabaykalsky Territory demonstrated its effectiveness. A prescription issued by a public medical organization is automatically transmitted to all connected commercial pharmacies (five pharmacies participated in the pilot project).

The pharmacy records the dispensing of the medication, and the prescription status is automatically updated for the physician.

Through the MILA mobile application, the patient can see the entire journey of the prescription — from issuance to readiness at the pharmacy.

This is not just data exchange but a closed digital ecosystem where everyone benefits: doctors, pharmacies, and most importantly, patients.

Prescription Data Exchange and Monitoring of Drug Stock Levels

Work on pharmaceutical supply management was strengthened not only in the region mentioned above.

In the Kamchatka Territory, integration with the Federal Preferential Drug Provision Registry (FRLLO) was expanded.

Thanks to our solution, in addition to prescription and benefits data, additional information can now be transmitted to the federal level, including:

• data on planned personalized needs of privileged patient categories for medical products
• requests for the supply of medical devices
• information on deliveries
• dispensing of medicines
• electronic certificates
• forecasts of drug consumption

In addition, a new product for drug stock data exchange was developed.

It enables pharmacies and warehouses to transmit information on the stock of medicines and medical devices to a unified regional repository.

Medical information systems receive access to up-to-date information about drug availability, which increases the accuracy of prescriptions and reduces the risk of shortages.

B2B Integrations: Connecting the Moscow Region EMIAS with Commercial Laboratories

The year 2025 also became an important stage in the development of the B2B integration direction.

We implemented integration with the Unified Medical Information and Analytical System (EMIAS) of the Moscow Region for laboratory diagnostics.

Now, requests from EMIAS are automatically sent to commercial laboratories. Once the laboratory completes the tests, the results are automatically returned to EMIAS via the API of the prescription data exchange service of the N3.Healthcare integration platform.

As a result, patients benefit the most, receiving their results faster.

Plans for 2026

We plan to replicate the success of the EMIAS integration in the commercial prescription market, enabling pharmacies and regional systems to operate within a unified digital environment.

Projects are also being developed to implement laboratory data exchange subsystems within the infrastructure of major medical information systems, ensuring direct interaction with commercial clinics.

Other products will continue to evolve as well, gaining new useful functionality with each update.